title: Ifosfamide-containing regimens for treating patients with osteosarcomas.
abstract: BACKGROUND
  This systemic analysis was conducted to evaluate the efficacy and safety of an ifosfamide- containing regimen in treating patients with osteosarcoma.
  
  
  METHODS
  Clinical studies evaluating the efficacy and safety of Ifosfamide-containing regimen on response and safety for patients with osteosarcoma were identified by using a predefined search strategy. Pooled response rate (RR) of treatment were calculated.
  
  
  RESULTS
  When ifosfamide-containing regimens were evaluated, 4 clinical studies which including 134 patients with osteosarcoma were considered eligible for inclusion. Systemic analysis suggested that, in all patients, pooled RR was 44.8% (60/134) in ifosfamide-containing regimens. Major adverse effects were neutropenia, leukopenia, and fatigue inIfosfamide-containing regimens; No treatment related death occurred in cantharidin combined regimens.
  
  
  CONCLUSIONS
  This systemic analysis suggests that ifosfamide-containing regimens are associated with good response rate and acceptable toxicity in treating patients with osteosarcoma, but this result should be confirmed by randomized clinical trials.
authors.affiliation: Department of Neurology, The Second People Hospital of Mudanjiang, Mudanjiang, China E-mail : yuboxxdd789@aliyun.com.
authors.forename: Yan-Yan
authors.initials: YY
authors.lastname: Li
authors.forename: Xiao-Ming
authors.initials: XM
authors.lastname: Jiang
authors.forename: Yi-Guo
authors.initials: YG
authors.lastname: Dong
authors.forename: Gang
authors.initials: G
authors.lastname: Xu
authors.forename: Yu-Bo
authors.initials: YB
authors.lastname: Ma
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage; D015251:Epirubicin / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D009367:Neoplasm Staging; D012516:Osteosarcoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D011379:Prognosis; D015996:Survival Rate
chemical_list: D015251:Epirubicin; D002945:Cisplatin; D007069:Ifosfamide